JP2005314255A - External preparation for skin which is suitable as anti-inflammatory quasi-drug - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide an emulsion dosage form wherein a phospholipid microsphere can stably exist. <P>SOLUTION: The phospholipid microsphere is contained in the emulsion containing fatty acid esters of polyglycerine. The emulsion preferably contains two fatty acid esters of polyglycerine, preferably a combination of an unsaturated fatty acid ester of decaglycerine and a saturated fatty acid ester of decaglycerine. The phospholipid microsphere preferably contains at least one chosen from sophoraflavanone G of formula 1, its salt and eugenol. <P>COPYRIGHT: (C)2006,JPO&NCIPI

Description

  The present invention relates to an external preparation for skin, and more particularly to an external preparation for skin suitable for quasi drugs.

  In external preparations for skin, a technique in which an active ingredient is encapsulated and administered in a phospholipid microsphere is considered to be a useful technique because it increases the stability of the active ingredient and improves the absorbability. (For example, refer to Patent Document 1, Patent Document 2, and Patent Document 3) However, phospholipid microspheres are stably present in an emulsion form in which an oil component having compatibility with a surfactant or phospholipid is present. This is accompanied by various difficulties, and therefore, a percutaneous absorption enhancement technique using phospholipid microspheres has not yet been applied. In other words, it can be said that development of an emulsifier form in which phospholipid microspheres can exist stably has been desired. Until now, as the hydrophilic surfactant used in such an emulsification system, a nonionic surfactant in the form of addition of polyoxyethylene has been mainly used. At present, anionic surfactants are combined. Other hydrophilic nonionic surfactants include polyoxybutylene polyglyceryl alkyl ether, polyglycerin fatty acid ester, and the like, but there are techniques for producing emulsions by combining these with phospholipids (for example, Patent Document 4, The combination with phospholipid microspheres is not known. In addition, a combination of phospholipid and kudin (for example, see Patent Document 7) and a combination of polyglycerin fatty acid ester and kudin (for example, see Patent Document 8) are already known. The technology of encapsulating in spheres and incorporating into the emulsion system containing polyglycerin fatty acid ester as a surfactant also makes it possible to stably incorporate phospholipid microspheres into the emulsion system by adopting such a configuration. Neither is known at all.

  It is already known that sophoraflavanone G is contained in legumes. It is also known to have a tyrosinase inhibitory action. (For example, refer nonpatent literature 1) About sophoraflavanone G, it is also known that antibacterial action, alpha-MSH inhibitory action, etc. exist. (See, for example, Patent Document 9, Patent Document 10, Patent Document 11, and Patent Document 12.) Eugenol is known to exist in flowers and / or buds of Syzygium aromaticum L.MERR.Et.PERRY. Since ancient times, it has been used as a fragrance component in cosmetics or as a healthy stomach crude drug in crude drugs. As other actions, an unpleasant odor masking action (see, for example, Patent Document 13), a dermal collagen fiber reconstruction promoting action (see, for example, Patent Document 14 and Patent Document 15), and the like are known. . Regarding the combination of kujin extract and clove extract, there are examples described in parallel with selectable examples of groups having similar properties (see, for example, Patent Document 16), but examples containing both in combination include In addition, it is difficult to obtain an extract containing sophoraflavanone G at a high concentration only by ordinary solvent extraction. Therefore, 1) 0.001 to 0.1% by mass of sophoraflavanone G and 2) 0.001 to eugenol There is no external preparation for skin comprising 1% by mass.

JP 2003-238387 A Japanese Patent Laid-Open No. 2003-113069 JP-A-5-286824 JP-A-7-316013 JP 2003-63996 A JP 2001-226221 A JP 2000-119155 A JP 2002-47123 A Japanese Patent Application Laid-Open No. 08-73364 JP 2000-44481 A JP 2001-220347 A JP 2003-95852 A JP 2004-123694 A JP 2002-104921 A JP 2002-255781 A JP 2002-3358 A Soo J. Kim et.al., Biol., Pharm., Bull., 26 (9), 1348-1350, (2003)

  The present invention has been made under such circumstances, and an object thereof is to provide an emulsifier form in which phospholipid microspheres can exist stably.

In view of such a situation, the present inventors have sought for an emulsifier form in which phospholipid microspheres can stably exist, and as a result of intensive research efforts, the present inventors contain polyglycerol fatty acid ester as a hydrophilic surfactant. The inventors have found that an emulsion system has such properties and have completed the invention. That is, the present invention is as follows.
(1) An external preparation for skin, which is an emulsion containing a fatty acid ester of polyglycerin, and further contains phospholipid microspheres.
(2) The external preparation for skin according to (1), comprising at least two kinds of fatty acid esters of polyglycerin.
(3) The skin external preparation according to (2), which contains an unsaturated fatty acid ester of decaglycerin and a saturated fatty acid ester of decaglycerin as the at least two kinds of fatty acid esters of polyglycerin.
(4) The phospholipid microsphere includes one or more selected from sophoraflavanone G, a salt thereof, and eugenol, wherein any one of (1) to (3) Item 1. An external preparation for skin according to item 1.

ソフォラフラバノンＧ

Sophora Flabanon G

(5) Sophoraflavanone G is contained in a form in which 0.00001 to 0.1% by mass and 2) Eugenol 0.0001 to 1% by mass are encapsulated in phospholipid microspheres, (1) to (4) The external preparation for skin according to any one of the above.
(6) The skin external preparation according to any one of (1) to (5), wherein the phospholipid constituting the wall of the phospholipid microsphere contains hydrogenated soybean phospholipid.
(7) The skin according to any one of (1) to (6), further comprising one or more selected from glycyrrhizic acid, alkyl glycyrrhetinate, and salts thereof. Topical agent.
(8) The content of one or more selected from the above glycyrrhizic acid, alkyl glycyrrhetinate and salts thereof is 0.01 to 0.5% by mass, (7) An external preparation for skin as described in 1. above.
(9) The external preparation for skin according to (7) or (8), which is a quasi-drug that promotes anti-inflammatory action.
(10) In the labeling, the indication that it is a quasi-drug that appealed to suppress the inflammation, and in its usage, take an appropriate amount, and include it in cut cotton etc. in the site with mild inflammation, Lightly rubbing it and applying it by pressing, indicating that it will be used by application, indicating that it reduces inflammation by applying, and stopping the use immediately if you feel tingling or burning The external preparation for skin according to (9), characterized in that the indication of the effect is constituted.

  According to the present invention, an emulsifier form in which phospholipid microspheres can exist stably can be provided.

(1) Fatty acid ester of polyglycerol which is an essential component of the external preparation for skin of the present invention The external preparation for skin of the present invention is characterized by containing a fatty acid ester of polyglycerin as an essential component. As the fatty acid ester of polyglycerin that can be used in the external preparation for skin of the present invention, it can be used without particular limitation as long as it is used in the external preparation for skin. Those having a degree of polymerization of glycerin of 5 to 15 are preferred, and those of 7 to 12 are particularly preferred. This is because it is preferable that the fatty acid of polyglycerin plays a role as a hydrophilic surfactant, and therefore there is preferably a hydrophilic group portion that only acts as a hydrophilic surfactant. Moreover, as a fatty acid residue, as long as it is generally known, it can be used without any particular limitation, for example, a linear fatty acid residue having 10 to 30 carbon atoms, a fatty acid residue having a branched chain, Fatty acid residues having a cyclic structure, fatty acid residues having an unsaturated bond and the like can be preferably exemplified. Specifically, for example, lauric acid residue, myristic acid residue, palmitic acid residue, stearic acid residue, behen Preferred examples include acid residues, isostearic acid residues, octyldodecanoic acid residues, oleic acid residues, linoleic acid residues, linolenic acid residues and the like. More preferable examples include a lauric acid residue, a stearic acid residue, an isostearic acid residue or an oleic acid residue. Moreover, 1-5 are preferable and, as for the presence number of the average fatty acid residue per molecule, 1-4 are more preferable. In the external preparation for skin of the present invention, such a fatty acid ester of polyglycerin can contain only one species or a combination of two or more species. A more preferred form is a form in which at least two fatty acid esters of polyglycerin are contained, and those having two or more different fatty acid residues and those having different average addition numbers of fatty acid residues may coexist. preferable. In the external preparation for skin of the present invention, the preferable content of the fatty acid ester of polyglycerin is 1 to 10% by mass, more preferably 3 to 7% by mass, based on the total amount of the external preparation for skin. is there. This is because if the amount is too small, an emulsion may not be formed. If the amount is too large, the stability of the emulsion may be impaired.

(2) Phospholipid globules which are essential components of the external preparation for skin of the present invention The external preparation for skin of the present invention is characterized by containing phospholipid microspheres as an essential component. As a component constituting the wall of the phospholipid microsphere, 80 to 95% by mass, more preferably 85 to 90% by mass of the phospholipid constituting the phospholipid is adjusted to be a hydrogenated phospholipid. Furthermore, it is preferable to contain 5 to 20% by mass, more preferably 10 to 15% by mass of glycosphingolipid with respect to the total amount of phospholipid. Such phospholipid microspheres can contain various active ingredients, thereby enhancing the percutaneous absorption of the active ingredients. As such an active ingredient, it can be applied without particular limitation as long as it is used in a skin external preparation such as cosmetics, but Soforaflavanone G and Eugenol are particularly preferable. The preferred content of sophoraflavanone G and / or a salt thereof in the external preparation for skin of the present invention is 0.00001 to 0.1 mass%, more preferably 0.00002 to 0.0005 mass%. Soforaflavanone G contains 10-50 mg in 1 kg of dried cucumber plant, and when water or the like is used as an extraction solvent, this component is difficult to elute and is usually extracted with ethanol or the like. When removed, an amorphous material containing 0.01 to 0.05% by mass of sophoraflavanone G is obtained. By liquid-liquid extraction of this extract with ethyl acetate and water and concentrating the ethyl acetate phase, an amorphous containing 0.1 to 1% by mass of sophoraflavanone G can be obtained. Further, a fraction containing 30-50% by mass of sophoraflavanone G can be obtained by fractionating and purifying the product by silica gel column chromatography (elution solvent chloroform, chloroform / methanol mixed solution). When extracting with ethanol from kujin, a rhizome can be particularly preferably exemplified as a plant part to be used. Extraction is done by chopping up the plant body, etc., adding 1 to 10 times the solvent to this, adding it to room temperature for several days, and if it is near the boiling point for several hours, soaking with appropriate stirring do it. Thereafter, the mixture is cooled to room temperature, and then an insoluble matter is removed by filtration, if desired, followed by concentration under reduced pressure to obtain amorphous. The fraction purification of this product is preferably carried out while checking the situation by thin layer chromatography or the like, and when this is a mixed solvent of chloroform (95 parts by volume) and methanol (5 parts by volume), It appears as a spot at about Rf 0.1. In the present invention, it is preferable that sophoraflavanone G is contained in the above-mentioned quantitative ratio in the form of a fraction / purified product of the leguminous cucumber extract. When it is contained, it is particularly preferred that it is contained in phospholipid microspheres together with eugenol described later. In the external preparation for skin of the present invention, sophoraflavanone G works together with eugenol described later to calm down a runaway inflammatory factor, cut off a vicious cycle of inflammation, and exert an action of preventing accumulation of injuries in the living body. Such an action is not preferable because the content of sophoraflavanone G in the external preparation for skin is less than 0.0001% by mass in the form of phospholipid spherules. Even if the content exceeds 0.01 mass%, the effect may reach its peak, which is not preferable. Below, the manufacture example of an extraction refinement | purification suitable for containing Sophoraflavanone G of such quantity ratio is shown. In the external preparation for skin of the present invention, it is preferable that the sophoraflavanone G is contained in a total amount of phospholipid microspheres.

<Production Example 1>
1 kg of dried leguminous rhizomes was chopped, 10 l of ethanol was added thereto, heated under reflux for 3 hours with stirring, cooled to room temperature, and concentrated under reduced pressure. To this was added 2 l of water and 2 l of ethyl acetate, solubilized, and liquid-liquid extraction was performed. The ethyl acetate phase was taken and concentrated to give 105 g of amorphous. The amount of sophoraflavanone G contained in this product was determined to be 0.9% by mass. (ODS column 4.6 mm × 150 mm, column temperature 40 ° C., elution solvent 30% acetonitrile aqueous solution, flow rate 1 ml / min, detection ultraviolet region 220 nm, quantitative by absolute calibration curve using standard substance) silica gel column chromatography (chloroform, chloroform When the methanol mixture was purified with an elution solvent), 1.2 g of amorphous containing 38% by mass of sophoraflavanone G was obtained. This was dissolved in 200 ml of 60% 1,3-butanediol aqueous solution to prepare Diluent 1.

  The external preparation for skin preferably contains eugenol as an essential component in an amount of 0.0001 to 1% by mass, more preferably 0.001 to 1% by mass. In such a content, such a component works with the sophoraflavanone G so as to calm down the runaway inflammatory factor, cut off the vicious cycle of inflammation, and exert the action of preventing the accumulation of injury in the living body. Eugenol is a component that has been used for a long time in the field of cosmetics as a fragrance component, and there are also commercially available products that are readily available. In addition, an extract such as clove containing a large amount of this is generally used in the cosmetic field. In the external preparation for skin of the present invention, such an ingredient can contain eugenol itself, or can be contained in the form of a herbal extract containing eugenol, such as an extract of clove. Particularly preferred is the inclusion in the form of an extract of clove, because, as shown in the examples below, it appears that substances other than the eugenol of the clove extract will enhance the action of eugenol. is there. A method for producing an extract suitable for the topical skin preparation of the present invention from clove is, for example, 1-50 parts by mass of a solvent per 1 part by mass of dried cider moths, which is a herb medicine clove. In addition, it may be immersed for several days at room temperature or for several hours at a temperature near the boiling point, cooled to room temperature, and filtered to remove insolubles as necessary. As the solvent used for such extraction, a polar solvent is preferable, and as the polar solvent, alcohol such as ethanol or water can be exemplified more preferably. Particularly preferred is water-containing alcohol, and the water content is preferably 5 to 20% by volume. This is because if the alcohol concentration is too high, coexisting substances other than the preferred eugenol cannot be eluted, and if the water content is too high, the extraction efficiency of eugenol may be reduced. By such extraction, an extract containing 200 to 500 g of eugenol per 1 kg of clove is obtained. A production example is shown below.

<Production Example 2>
5 kg of 85% ethanol (containing 15% water) was added to 1 kg of dried cypress mushrooms, and the mixture was heated to reflux for 3 hours. After cooling to room temperature, insoluble materials were removed by filtration, and the filtrate was concentrated under reduced pressure to obtain 215 g of an extract. This contained 87.7% by mass of eugenol.

  Such eugenol is preferably encapsulated in a phospholipid microsphere together with the sophoraflavanone G and then contained in an external preparation for skin.

  The sophoraflavanone G or eugenol may be encapsulated in phospholipid microspheres by a generally known method. For example, phospholipid is dissolved in a polyhydric alcohol in advance, and this contains water. Gradually added to the aqueous phase to create an emulsion, and using a high-pressure emulsifier such as an extruder or microfluidizer, the system of small spheres may be uniformly prepared.

(3) External preparation for skin of the present invention The external preparation for skin of the present invention contains the above-mentioned essential components, suppresses inflammation that continuously induces a vicious circle induced by irradiation with a high dose of ultraviolet rays, and occurs by irradiation with a high dose of ultraviolet rays. It has the effect of making injuries caused by inflammation lighter. By such an effect, a living body attack reaction caused by an inflammatory factor caused by prolonged inflammation can be suppressed mildly, and a living body damage can be reduced. In the external preparation for skin of the present invention, it is preferable to contain an active ingredient used for UV damage in addition to the above essential ingredients. Examples of the active ingredient include indomethacin, ketoprofen, glycyrrhizic acid and Preferred examples include / and salts thereof, anti-inflammatory agents such as glycyrrhetinic acid and / or esters thereof. As the anti-inflammatory agent, glycyrrhizic acid and / or a salt thereof, glycyrrhetinic acid and / or an alkyl ester thereof is more preferable. Glycyrrhizic acid and / or its salt is preferably dipotassium glycyrrhizinate, and alkyl glycyrrhetinate and / or its salt is preferably stearyl glycyrrhetinate. Such ingredients are known as active ingredients of quasi-drugs, and if these ingredients can be stably blended, quasi-drugs that have demonstrated anti-inflammatory effects by containing these components in predetermined amounts. It can be. This is because high-dose ultraviolet irradiation is stable and safe. The preferable content of such components is 0.01 to 0.5% by mass and 0.03 to 0.1% by mass with respect to the total amount of the external preparation for skin. This is because if the amount is too small, the effect may not be achieved, and if the amount is too large, the effect may reach a peak.

  In the external preparation for skin of the present invention, in addition to the above-mentioned components, optional components that are usually used in cosmetics and external preparations for skin can be contained. Such optional ingredients include, for example, macadamia nut oil, avocado oil, corn oil, olive oil, rapeseed oil, sesame oil, castor oil, safflower oil, cottonseed oil, jojoba oil, coconut oil, palm oil, liquid lanolin, hydrogenated coconut oil Oils such as hardened oil, mole, hardened castor oil, beeswax, candelilla wax, carnauba wax, ibotarou, lanolin, reduced lanolin, hard lanolin, jojoba wax, waxes, liquid paraffin, squalane, pristane, ozokerite, paraffin, ceresin, petrolatum , Hydrocarbons such as microcrystalline wax, higher fatty acids such as oleic acid, isostearic acid, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, undecylenic acid, cetyl alcohol, stearyl alcohol, isostearyl Alcohol, behenyl alcohol, octyldodecanol, higher alcohol such as myristyl alcohol, cetostearyl alcohol, cetyl isooctanoate, isopropyl myristate, hexyldecyl isostearate, diisopropyl adipate, di-2-ethylhexyl sebacate, cetyl lactate, malic acid Diisostearyl, di-2-ethylhexanoic acid ethylene glycol, dicaprate neopentyl glycol, di-2-heptylundecanoic acid glycerin, tri-2-ethylhexanoic acid glycerin, tri-2-ethylhexanoic acid trimethylolpropane, tri Synthetic ester oils such as trimethylolpropane isostearate and pentane erythritol tetra-2-ethylhexanoate, dimethylpolysiloxane, methylphenylpoly Loxane, linear polysiloxane such as diphenylpolysiloxane, cyclic polysiloxane such as octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, dodecamethylcyclohexanesiloxane, amino-modified polysiloxane, polyether-modified polysiloxane, alkyl-modified polysiloxane, Oil agents such as silicone oil such as modified polysiloxane such as fluorine-modified polysiloxane, anionic surfactants such as fatty acid soap (sodium laurate, sodium palmitate, etc.), potassium lauryl sulfate, triethanolamine ether of alkyl sulfate, chloride Cationic surfactants such as stearyltrimethylammonium chloride, benzalkonium chloride, laurylamine oxide, imidazoline-based amphoteric surfactants (2-cocoyl-2-imida Zolinium hydroxide-1-carboxyethyloxy disodium salt, etc.), betaine surfactants (alkyl betaine, amide betaine, sulfobetaine, etc.), amphoteric surfactants such as acylmethyltaurine, sorbitan fatty acid esters (sorbitan) Monostearate, sorbitan sesquioleate, etc.), glycerin fatty acids (glyceryl monostearate, etc.), propylene glycol fatty acid esters (propylene glycol monostearate, etc.), hardened castor oil derivatives, glycerin alkyl ethers, POE sorbitan fatty acid esters (POE sorbitan monooleate, polyoxyethylene sorbitan monostearate, etc.), POE sorbite fatty acid esters (POE-sorbitol monolaurate, etc.), POE glycerin fatty acid ester Tells (POE-glycerol monoisostearate, etc.), POE fatty acid esters (polyethylene glycol monooleate, POE distearate, etc.), POE alkyl ethers (POE2-octyldodecyl ether, etc.), POE alkyl phenyl ethers (POE nonylphenyl) Ethers, etc.), Pluronic types, POE / POP alkyl ethers (POE / POP2-decyltetradecyl ether, etc.), Tetronics, POE castor oil / hardened castor oil derivatives (POE castor oil, POE hardened castor oil, etc.), Nonionic surfactants such as sucrose fatty acid ester and alkyl glucoside, polyethylene glycol, glycerin, 1,3-butylene glycol, erythritol, sorbitol, xylitol, maltitol, propylene Polyols such as recall, dipropylene glycol, diglycerin, isoprene glycol, 1,2-pentanediol, 2,4-hexylene glycol, 1,2-hexanediol, 1,2-octanediol, pyrrolidone carboxylic acid Moisturizing ingredients such as sodium, lactic acid, sodium lactate, guar gum, quince seed, carrageenan, galactan, gum arabic, pectin, mannan, starch, xanthan gum, curdlan, methylcellulose, hydroxyethylcellulose, carboxymethylcellulose, methylhydroxypropylcellulose, chondroitin sulfate , Dermatan sulfate, glycogen, heparan sulfate, hyaluronic acid, sodium hyaluronate, tragacanth gum, keratan sulfate, chondroitin, mucoitin sulfate, hyaluronan Droxyethyl guar gum, carboxymethyl guar gum, dextran, keratosulfuric acid, locust bean gum, succinoglucan, caronic acid, chitin, chitosan, carboxymethylchitin, agar, polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, sodium polyacrylate, Thickeners such as polyethylene glycol and bentonite, surface may be treated, powder such as mica, talc, kaolin, synthetic mica, calcium carbonate, magnesium carbonate, silicic anhydride (silica), aluminum oxide, barium sulfate The surface may be treated, bengara, yellow iron oxide, black iron oxide, cobalt oxide, ultramarine, bitumen, titanium oxide, zinc oxide inorganic pigments, the surface may be treated, mica titanium, Fish phosphorus foil, bismuth oxychloride Pearl agents, which may be raked Red 202, Red 228, Red 226, Yellow 4, Blue 404, Yellow 5, Red 505, Red 230, Red 223, Orange 201 No., Red No. 213, Yellow No. 204, Yellow No. 203, Blue No. 1, Green No. 201, Purple No. 201, Red No. 204, and the like, polyethylene powder, polymethyl methacrylate, nylon powder, organopolysiloxane elastomer Organic powders such as paraaminobenzoic acid UV absorbers, anthranilic acid UV absorbers, salicylic acid UV absorbers, cinnamic acid UV absorbers, benzophenone UV absorbers, sugar UV absorbers, 2- ( 2′-hydroxy-5′-t-octylphenyl) benzotriazole, 4-methoxy-4′-t-butyldibenzoylmethane, etc. External line absorbers, lower alcohols such as ethanol and isopropanol, vitamin A or its derivatives, vitamin B6 hydrochloride, vitamin B6 tripalmitate, vitamin B6 dioctanoate, vitamin B2 or its derivatives, vitamin B12, vitamin B15 or its derivatives, etc. Vitamin E such as vitamin B, α-tocopherol, β-tocopherol, γ-tocopherol, vitamin E acetate, vitamin D, vitamin H, pantothenic acid, panthetin, pyrroloquinoline quinone, and the like can be preferably exemplified . Among these, in the external preparation for skin of the present invention, the content of the nonionic surfactant added with polyoxyethylene is preferably at most 1% by mass in order to enhance the stability of the phospholipid microspheres. It is preferable to keep it at 0.7% by mass. The skin external preparation of this invention can be manufactured by processing these according to a conventional method.

  Hereinafter, the present invention will be described in more detail with reference to examples, but it goes without saying that the present invention is not limited to such examples.

  In accordance with the formulation shown below, emulsion 1 (cosmetics; quasi-drugs that appealed anti-inflammatory) as an external preparation for skin of the present invention was prepared. Prior to the preparation of the emulsion, phospholipid spherules to be blended therein were prepared in advance. That is, the components of a) and b) were heated to 70 ° C., and b) was gradually added to b) with stirring to prepare a crude emulsion, which was then used as a high-pressure emulsifier “Microfluidizer” (MFI). Manufactured) to prepare small spheres, stirred and cooled to obtain intermediate work-in-process products for producing emulsions. Next, the components c) and d) are heated to 80 ° C., respectively, and d) is gradually added to C) with stirring. The mixture is cooled with stirring, and at 40 ° C., the phospholipid globule of e) is added, The emulsion was cooled to room temperature.

(Phospholipid globules 1)
B)
Hydrogenated soybean phospholipid 2.1% by mass
Soybean phospholipid 0.3% by mass
Glycosphingolipid 0.3% by mass
Glycerin 21.4% by mass
1,3-butanediol 14.2% by mass
Diluent 1 (Production Example 1) 0.3% by mass
(Soforaflavanone G0.000684%)
Extract (Production Example 2) 0.3% by mass
(Eugenol 0.2631% by mass)
Royal jelly 1,3-butanediol extract 3% by mass
B)
Soy protein 0.3% by mass
Soybean isoflavone glycoside 3% by mass
54.8% by weight of water

C)
Squalane 8% by mass
N-lauroyl-L-glutamate di (phytosteryl / octyldodecyl)
“El Dew PS-203” (manufactured by Ajinomoto Co., Inc.) 5% by mass
Macadamia nut oil 2% by mass
Stearyl alcohol 2.5% by mass
Stearic acid 1% by mass
Stearyl glycyrrhetinate 10% aqueous solution 0.5% by mass
Hydrogenated phospholipid 0.2% by mass
D)
Decaglycerin tristearate 2% by mass
Decaglycerin monooleate 2% by mass
Methylparaben 0.3% by mass
Phenoxyethanol 0.3% by mass
Glycerin 53.7% by mass
Diglycerin 3% by mass
Quince extract 2% by mass
POE (20) behenyl ether 0.5% by mass
1,3-butanediol 8% by mass
5.5% by weight of water
E)
Phospholipid spherule 1 3.5% by mass
(Sophoraflavanone G0.0000228% by mass,
Eugenol 0.088% by mass)

<Test Example 1>
The effect of emulsion 1 on inflammation was confirmed using 5 panelists. That is, three 2 cm × 3 cm portions were created on the back of the panel, and two of these were irradiated with ultraviolet rays (light source SE lamp) that was 1.8 times the minimum erythema dose (MED) determined in advance. Two days later, after confirming that the transdermal water dispersion loss (TEWL) had increased, specimens were administered to three of them. One specimen was emulsion 1, the remaining one was used as an irradiation control, and the non-irradiated site was used as an untreated control. TEWL was measured again 24 hours after administration. The results are shown in Table 1. From this, it can be seen that according to the external preparation for skin of the present invention, the adverse effects of ultraviolet irradiation can be quickly sedated. That is, it was confirmed that the percutaneous absorbability was increased by containing an active ingredient in the phospholipid microspheres.

<Test Example 2>
The stability of phospholipid microspheres in Emulsion 1 was confirmed. That is, the emulsion 1 was stored at 40 ° C. for 1 month and observed under a microscope to observe the shape of phospholipid microspheres. As an index for observation, the percentage of normal-shaped microspheres with respect to the total number of microspheres in five visual fields under a microscope was used. At the same time, Comparative Example 1 in which decaglycerin tristearate and decaglycerin monooleate were substituted with POE (20) behenyl ether was similarly prepared and a stability test was performed. The results are shown in Table 2. From this, it can be seen that in the external preparation for skin of the present invention, the stability of the phospholipid microspheres is excellent, and this stability is derived from the fatty acid ester of polyglycerol.

  In the same manner as in Example 1, an emulsion 2 was prepared according to the following formulation, and a stability test was conducted in the same manner as in Test Example 2. The proportion of normal microspheres after storage at 40 ° C. for 1 month was 95.3%, and it was found that a form containing two types of polyglycerin fatty acid esters was preferable.

(Phospholipid globules 1)
B)
Hydrogenated soybean phospholipid 2.1% by mass
Soybean phospholipid 0.3% by mass
Glycosphingolipid 0.3% by mass
Glycerin 21.4% by mass
1,3-butanediol 14.2% by mass
Diluent 1 (Production Example 1) 0.3% by mass
(Sophora Flavanone G 0.00002394% by mass,
Extract (Production Example 2) 0.3% by mass
(Eugenol 0.2631% by mass)
Royal jelly 1,3-butanediol extract 3% by mass
B)
Soy protein 0.3% by mass
Soybean isoflavone glycoside 3% by mass
54.8% by weight of water

C)
Squalane 8% by mass
N-lauroyl-L-glutamate di (phytosteryl / octyldodecyl)
“El Dew PS-203” (manufactured by Ajinomoto Co., Inc.) 5% by mass
Macadamia nut oil 2% by mass
Stearyl alcohol 2.5% by mass
Stearic acid 1% by mass
Stearyl glycyrrhetinate 10% aqueous solution 0.5% by mass
Hydrogenated phospholipid 0.2% by mass
D)
Decaglycerin monooleate 4% by mass
Methylparaben 0.3% by mass
Phenoxyethanol 0.3% by mass
Glycerin 53.7% by mass
Diglycerin 3% by mass
Quince extract 2% by mass
POE (20) behenyl ether 0.5% by mass
1,3-butanediol 8% by mass
5.5% by weight of water
E)
Phospholipid spherule 1 3.5% by mass
(Sophora Flavanone G 0.00002394% by mass,
Eugenol 0.088% by mass)

  In the same manner as in Example 1, an emulsion 3 was prepared according to the following formulation, and a stability test was conducted in the same manner as in Test Example 2. The proportion of normal microspheres after storage at 40 ° C. for 1 month is 96.2%, and is incorporated as a fatty acid ester of at least two kinds of polyglycerol in combination with an ester of an unsaturated fatty acid and an ester of a saturated fatty acid. Was found to be preferable.

(Phospholipid globules 1)
B)
Hydrogenated soybean phospholipid 2.1% by mass
Soybean phospholipid 0.3% by mass
Glycosphingolipid 0.3% by mass
Glycerin 21.4% by mass
1,3-butanediol 14.2% by mass
Diluent 1 (Production Example 1) 0.3% by mass
(Soforaflavanone G0.000684%)
Extract (Production Example 2) 0.3% by mass
(Eugenol 0.2631% by mass)
Royal jelly 1,3-butanediol extract 3% by mass
B)
Soy protein 0.3% by mass
Soybean isoflavone glycoside 3% by mass
54.8% by weight of water

C)
Squalane 8% by mass
N-lauroyl-L-glutamate di (phytosteryl / octyldodecyl)
“El Dew PS-203” (manufactured by Ajinomoto Co., Inc.) 5% by mass
Macadamia nut oil 2% by mass
Stearyl alcohol 2.5% by mass
Stearic acid 1% by mass
Stearyl glycyrrhetinate 10% aqueous solution 0.5% by mass
Hydrogenated phospholipid 0.2% by mass
D)
Decaglycerin monostearate 2% by mass
Decaglycerin tristearate 2% by mass
Methylparaben 0.3% by mass
Phenoxyethanol 0.3% by mass
Glycerin 53.7% by mass
Diglycerin 3% by mass
Quince extract 2% by mass
POE (20) behenyl ether 0.5% by mass
1,3-butanediol 8% by mass
5.5% by weight of water
E)
Phospholipid spherule 1 3.5% by mass
(Sophora Flavanone G 0.00002394% by mass,
Eugenol 0.088% by mass)

  The present invention can be applied to an external preparation for skin in which phospholipid microspheres are stably blended.

Claims (10)

A skin external preparation characterized by being an emulsion containing a fatty acid ester of polyglycerin and further containing phospholipid microspheres. The skin external preparation according to claim 1, comprising at least two types of fatty acid esters of polyglycerin. The skin external preparation according to claim 2, comprising an unsaturated fatty acid ester of decaglycerin and a saturated fatty acid ester of decaglycerin as the fatty acid ester of at least two kinds of polyglycerin. The phospholipid microsphere includes one or more selected from sophoraflavanone G, a salt thereof and eugenol, according to any one of claims 1 to 3. Skin external preparation.

Sophora Flabanon G Either of Soforaflavanone G is contained in a form of 0.00001-0.1% by mass and 2) Eugenol 0.0001-1% by mass in a phospholipid microsphere. Item 1. An external preparation for skin according to item 1. The skin external preparation according to any one of claims 1 to 5, wherein the phospholipid constituting the wall of the phospholipid microsphere contains hydrogenated soybean phospholipid. The skin external preparation according to any one of claims 1 to 6, further comprising one or more selected from glycyrrhizic acid, alkyl glycyrrhetinate, and salts thereof. The content of one or more selected from the glycyrrhizic acid, alkyl glycyrrhetinate and salts thereof is 0.01 to 0.5% by mass, according to claim 7. Skin external preparation. The external preparation for skin according to claim 7 or 8, which is a quasi-drug that promotes anti-inflammatory action. In the labeling, the indication that it is a quasi-drug that appealed to suppress the inflammation, and in its usage, take an appropriate amount and include it in cut cotton etc. in a lightly inflamed area, and lightly An indication that it is applied and used by rubbing and pressing operation, an indication that inflammation is suppressed by the application, and an indication that use is stopped immediately if a feeling of irritation or burning is felt by the above operation The external preparation for skin according to claim 9, wherein: